BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
May 10, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CUDC-101: Completed Phase I enrollment

Curis completed enrollment of 25 patients in an open-label, dose-escalation, U.S. Phase I trial to evaluate intravenous CUDC-101.

Curis Inc. (NASDAQ:CRIS), Cambridge, Mass.
Product: CUDC-101...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >